Can a Brain Tumor Be Monitored Rather Than Treated Right Away? When Surveillance Is Chosen

The scan was ordered for a stubborn sinus infection. Two weeks later, a woman in her sixties sat across from a neurosurgeon who said the sentence she never expected to hear: “There is a small tumor on your brain, and my advice is that we watch it.” She had braced for an operating date. Instead she got a follow-up appointment in six months and a leaflet about MRI.

That reaction is common. Most of us have absorbed the idea that a tumor is something you remove, fast, before it does harm. So the question people type into search engines at midnight, when can a brain tumor be monitored, is really two questions: is watching genuinely safe, and how will anyone know if the moment to act arrives?

The honest answer is that surveillance is a considered medical strategy, not a shrug. It rests on what the tumor looks like, where it sits, how the person feels, and how the balance of risks shifts over time.

What does "monitoring" a brain tumor actually mean?

Monitoring, also called active surveillance or watch and wait, means a tumor is left in place and tracked with scheduled imaging and clinical check-ups rather than removed or irradiated right away. The word “active” matters. Nobody is ignoring the tumor; the team is measuring it.

The workhorse of surveillance is MRI, magnetic resonance imaging, a scan that uses strong magnets and radio waves rather than X-rays to build detailed pictures of soft tissue. The first scan after diagnosis becomes the baseline: a set of measurements in millimeters that every later scan is compared against. Radiologists look at three things on each follow-up. Has the tumor changed size? Has its appearance changed, for example a new area that lights up with contrast dye? Is there any swelling in the surrounding brain, which appears as a bright halo on certain MRI sequences?

Alongside imaging, the person is asked about symptoms at each visit, and sometimes examined for subtle changes in strength, coordination, vision or hearing. For tumors near the pituitary gland, blood tests that check hormone levels may be part of the routine. For tumors on the hearing nerve, a hearing test often is.

Surveillance is usually run by a team rather than a single doctor: a neurosurgeon, a neuro-oncologist (a specialist in tumors of the nervous system), a neuroradiologist who reads the scans, and often a specialist nurse who acts as the day-to-day contact. The plan they agree is provisional by design. Mayo Clinic describes observation for small, symptom-free meningiomas as a strategy of periodic brain scans to check whether the tumor is growing, with treatment reconsidered if it does.

When can a brain tumor be monitored? The features that tip the balance

No single measurement decides this. Neurosurgeons weigh a cluster of features, and the more of them that line up, the more comfortable everyone is with watching.

The first is what the tumor is likely to be. Some tumors have a characteristic look on MRI; a meningioma, for instance, typically sits on the brain’s surface, attached to its covering membranes, and enhances brightly and evenly with contrast. When the imaging pattern strongly suggests a slow-growing, non-cancerous type, surveillance becomes a realistic option. When it suggests a fast-growing or cancerous tumor, it usually does not.

Size and location come next. A small tumor tucked in a quiet region of the brain is a very different proposition from one pressing on the optic nerves, the brainstem or the channels that drain cerebrospinal fluid. Location often matters more than size. A modest tumor in a critical spot may need action sooner than a larger one elsewhere.

Then there is the person. Are there symptoms that can be pinned to the tumor? Is there swelling around it, which suggests it is irritating the brain? How old is the patient, and what other health conditions would make an operation riskier? Someone in their late seventies with heart disease and a tiny, silent meningioma faces a different risk calculation from someone in their thirties with the same finding, because the younger person has many more decades in which the tumor could grow.

Preference counts too. Some people cannot tolerate the idea of a tumor sitting in their head; others would far rather avoid surgery unless it becomes necessary. Both positions are legitimate, and a good team will say so. Mayo Clinic frames the observation choice in exactly these terms: small, slow growing, no symptoms, and regular scans to confirm nothing has changed.

Who is usually offered surveillance, and who is usually asked not to wait?

The typical surveillance candidate is someone whose tumor was found by accident. Scans for headaches after a minor car accident, for dizziness, for hearing loss or as part of a research study turn up unexpected findings often enough that radiologists have a word for them: incidentalomas. These tumors are, by definition, not causing the problem that prompted the scan. Many are small, and many will never cause any problem at all.

Older adults are more often offered watching, partly because meningiomas become more common with age and partly because the risks of a long operation rise with age and with other illnesses. People with complex medical histories, on blood thinners, or with lung or heart conditions may be steered toward observation for the same reason. So may anyone whose tumor sits in a location where surgery carries a high chance of causing new deficits.

Who is usually asked not to wait? Anyone with symptoms clearly caused by the tumor: seizures, progressive weakness, worsening vision or a sustained change in personality or thinking. Anyone whose scan shows significant swelling in the surrounding brain, or signs that fluid pathways are blocked. Hydrocephalus, a build-up of cerebrospinal fluid that raises pressure inside the skull, is an urgent reason to act. Tumors with imaging features that raise suspicion of cancer, whether a primary brain cancer or a spread from cancer elsewhere, usually need a tissue diagnosis rather than a waiting period, because the treatment pathway depends on knowing exactly what the tumor is.

The NHS notes that treatment for a benign brain tumor depends on type, location, size and general health, and that some tumors are treated because they are causing symptoms while others are simply monitored. That sentence is the whole triage in miniature.

Meningioma watch and wait: the most common surveillance story

If you meet someone being monitored for a brain tumor, the odds are it is a meningioma. A meningioma grows from the meninges, the layered membranes that wrap the brain and spinal cord, rather than from brain tissue itself. Cleveland Clinic reports that meningiomas account for roughly 30% of all primary brain tumors, making them the most common type diagnosed in adults, and that most are non-cancerous.

Meningiomas are graded by the World Health Organization system on a scale of 1 to 3. Grade 1 tumors, the great majority, are slow growing with well-defined edges. Grade 2 tumors grow faster and are more likely to return after removal. Grade 3 tumors are cancerous and behave aggressively. Grade can only be confirmed by examining tissue, so a meningioma under surveillance is, strictly speaking, a presumed grade 1 tumor based on how it looks and how it behaves over time.

Several imaging clues nudge a surgeon toward watching. Calcification, flecks of calcium visible on a CT scan, tends to indicate a tumor that has been there a long time and is growing slowly. A tumor that appears dark on certain MRI sequences and has no surrounding brain swelling behaves more predictably than one that is bright and edematous. A dural tail, a thin ribbon of enhancement extending along the membrane from the tumor, helps confirm the diagnosis.

What ends watching for a meningioma is not usually a dramatic event but a trend: steady growth across two or three scans, or the first symptom that can be attributed to the tumor. Even then, growth alone does not force surgery. Mayo Clinic lists observation, surgery and radiation therapy as the main approaches, and the choice among them turns on the same variables that justified watching in the first place.

Acoustic neuromas, pituitary tumors and low-grade gliomas: how surveillance differs

Meningiomas are not the only tumors that get watched, but each type comes with its own logic and its own trigger points.

Tumor type	What it is	Why watching may be offered	What typically prompts a change of plan
Meningioma	Tumor of the brain’s covering membranes; most are non-cancerous	Small, calcified, no symptoms, no swelling, older age	Measurable growth over successive scans; new symptoms
Acoustic neuroma (vestibular schwannoma)	Non-cancerous tumor on the balance and hearing nerve	Small size; hearing still useful; slow or no growth	Growth toward the brainstem; worsening hearing or balance
Non-functioning pituitary adenoma	Non-cancerous growth in the hormone gland below the brain	No hormone excess; no pressure on optic nerves	Vision changes; hormone deficiency; growth on MRI
Low-grade glioma	Slow-growing tumor from the brain’s supporting cells	Occasionally, for very small, symptom-free lesions	Any growth, new contrast enhancement, seizures

Acoustic neuromas are the second classic watch-and-wait tumor. They grow on the nerve linking the inner ear to the brain, and Mayo Clinic notes that many grow slowly or not at all. Because surgery and radiation both carry a risk to hearing, watching a small tumor while hearing remains useful is a reasonable trade. Regular hearing tests join the MRI schedule.

Pituitary adenomas fall into two camps. Those that pump out excess hormone usually need treatment to control the hormone problem. Those that do not, called non-functioning adenomas, can often be watched if they are not pressing on the optic nerves that run just above the gland. Johns Hopkins describes vision testing and hormone blood work as standard parts of pituitary evaluation.

Gliomas are different. They arise from brain tissue itself and, even when low grade, tend to grow and can transform into more aggressive forms. Surveillance is the exception rather than the rule, reserved for selected small, silent lesions, and it tends to be short-lived.

How often are MRI scans done during brain tumor monitoring?

People want a schedule, and the truthful reply is that the schedule is front-loaded and then relaxes if the tumor behaves.

After the baseline scan, most teams arrange a second MRI within the first several months. This early repeat has one job: to catch a tumor that is growing quickly, because those are the ones where waiting would be a mistake. If the second scan matches the first, the interval usually widens. Mayo Clinic describes monitoring for acoustic neuromas with imaging typically every 6 to 12 months, a pattern that is broadly similar for small meningiomas. After several years of stability, some teams stretch intervals further still, and for very stable, calcified tumors in older adults, surveillance may eventually be paused altogether. That decision is individual, and it belongs to the treating team.

Most surveillance scans use gadolinium contrast, an injected dye that makes tumors stand out against normal brain. The scan itself takes roughly half an hour to an hour depending on the sequences ordered, and MRI involves no ionizing radiation, so there is no accumulating radiation risk from repeated scans. People with kidney disease, pacemakers or certain implants may need adjusted protocols, which the imaging department will ask about in advance.

What radiologists measure has grown more precise. Older reports quoted a single largest diameter; many centers now calculate volume, which detects subtle growth that a diameter alone can miss. Ask whether your reports include volumes, and ask for copies. A folder of your own reports, with the numbers side by side, turns an abstract worry into something you can see.

One caution about reading your own scans: small differences between reports can reflect how the head was positioned or which slice the measurement was taken from. A change of a millimeter or two on one scan is a question for the radiologist, not a verdict.

What the first weeks after a "let's watch" decision usually look like

The strangest part of surveillance is how little happens. After the consultation there is, typically, a letter summarizing the plan, a scan booked for a date months away, and an invitation to call if anything changes. Some people find the quiet reassuring. Many find it unnerving.

A few practical things do tend to happen early. If the tumor sits near the hearing nerve, an audiogram, a formal hearing test in a soundproof booth, establishes a baseline. If it sits near the optic pathways, an eye specialist may map your visual fields. Pituitary tumors bring a round of morning blood tests to check hormone levels. None of these are treatments; they are more baselines, so that later changes can be measured.

Driving is the question that catches people off guard. In most jurisdictions, a brain tumor diagnosis by itself does not affect a driving license, but a seizure does, and rules vary by country and by license type. Ask your team directly, and check your licensing authority’s guidance rather than relying on memory.

Work usually continues as normal. There is no medical reason to stop exercising, traveling or drinking a glass of wine because a silent tumor has been found, though it is sensible to tell any doctor treating you for anything else, and to carry a note of the diagnosis when you travel.

The emotional timeline is less tidy. A wave of anxiety before each scan, sometimes nicknamed scanxiety, is so common that specialist nurses expect it. It tends to ease as stable scans accumulate, but it rarely disappears. Telling your team that you are struggling is not a weakness in the plan; it is information they can act on, whether with counseling, a support group referral or simply more frequent contact.

What happens if the tumor grows on a scan?

Growth is the event surveillance is designed to catch, so it helps to know in advance what it does and does not mean.

It does not automatically mean surgery. A meningioma that has grown a couple of millimeters over two years is behaving like a typical grade 1 meningioma, and the team may simply tighten the scan interval. What changes the conversation is the pace of growth, a new symptom, new swelling in the surrounding brain, or growth toward a structure that would make later treatment harder. Surgeons think ahead: a tumor that is easy to remove today but would be wrapped around a major artery in five years may be better dealt with early even though it is silent.

If treatment is recommended, there are usually two broad routes. Surgery aims to remove the tumor, or as much of it as can be taken safely, and provides tissue for a definitive diagnosis. Radiation comes in two forms. Stereotactic radiosurgery delivers a single high dose of very focused beams to the tumor, without any incision, and is often considered for small tumors in awkward locations. Fractionated radiotherapy spreads smaller doses across several weeks and is used for larger tumors or those close to sensitive structures. The NHS lists surgery and radiotherapy as the main treatments for benign brain tumors, chosen according to type, position and size.

Each route has risks, which your team will lay out for your specific tumor: infection, bleeding and new neurological deficits with surgery; swelling, fatigue and delayed effects on nearby nerves with radiation. A second opinion is a reasonable request at this point and is rarely taken amiss.

Growth also sometimes changes nothing. For a very frail person with a slowly enlarging tumor, continuing to watch may remain the wisest course, and a good team will say so plainly.

Managing symptoms while watching and waiting

Surveillance is offered when a tumor is causing no symptoms, so in theory there is nothing to manage. Real life is untidier. People with a known brain tumor notice every headache, every moment of dizziness, and need a way to tell background noise from signal.

Headaches are the most common worry. The overwhelming majority of headaches in people under surveillance are the same tension-type or migraine headaches they had before the diagnosis, and treating them as such, with sleep, hydration, regular meals and the usual over-the-counter approaches agreed with your doctor, is appropriate. The pattern to report is described in the red-flag section below: a new kind of headache, one that wakes you or is worst on waking, or one accompanied by vomiting or neurological symptoms.

Seizures are the symptom most likely to move someone from watching to treating. If a seizure does occur, the team will typically start an anti-seizure medicine, a class of drugs that stabilize electrical activity in the brain, and reassess the tumor. The choice, dose and duration are decisions for the prescribing clinician, and stopping such a medicine without discussion is never advisable.

Corticosteroids are sometimes mentioned in the context of brain tumors. Their role is to reduce swelling in the brain around a tumor, and they are usually short-term, used around surgery or when swelling causes symptoms. They are not a surveillance medicine, and someone under observation would not normally be taking them.

For acoustic neuromas, hearing loss and imbalance are the symptoms to track. Hearing aids, vestibular rehabilitation (balance exercises taught by a physiotherapist) and simple safety measures at home can make a measurable difference while the tumor itself is watched. The NHS describes regular hearing checks and MRI as the core of acoustic neuroma monitoring.

How long can a brain tumor go undiagnosed?

Years, in many cases. That answer surprises people, but it follows directly from why surveillance works at all.

The brain is remarkably adaptable to slow change. A tumor that enlarges by a millimeter or two a year gives surrounding tissue time to shift and compensate, so function is preserved long after the tumor would have been visible on a scan. The NHS describes benign brain tumors as growing slowly, sometimes over many years, which is why so many are picked up incidentally on scans done for other reasons rather than because of symptoms.

The flip side is that when symptoms do appear from a slow-growing tumor, the tumor is often already sizeable. The clue in retrospect is frequently vague: a subtle change in personality that family noticed but attributed to stress, a gradual loss of hearing in one ear blamed on age, headaches that were put down to screen time. None of these is specific, and none of them should be read as evidence that a tumor is present. Most people with these complaints have something else entirely.

Fast-growing tumors are the mirror image. A high-grade glioma can go from invisible to symptomatic within months, and symptoms tend to be more abrupt: a first seizure in an adult, rapidly progressive weakness, a sudden change in speech. These are not tumors that go undiagnosed for years, and they are not tumors that get watched.

The practical lesson is not to scan everyone with a headache. It is that a diagnosis made incidentally, when the tumor is small and silent, is in many ways the best possible circumstance in which to find one, because it hands the person and their team the widest range of options, including the option of doing nothing for now.

What is commonly mistaken for a brain tumor, and the other way round?

Two kinds of mistake sit on either side of this question, and both are worth understanding.

The first is a person convinced they have a tumor when they do not. Migraine is the great impersonator: it can bring visual disturbances, numbness down one side, difficulty finding words and pounding headache, a combination that reads like a textbook tumor description. Tension-type headache, sinus disease, inner-ear disorders that cause vertigo, and anxiety with its dizziness and poor concentration all generate the search query “do I have a brain tumor” far more often than tumors do. Multiple sclerosis and transient ischemic attacks (brief stroke-like episodes) can also mimic tumor symptoms and sometimes require the same MRI to sort out. The NHS is explicit that brain tumor symptoms overlap with many common conditions, and that a persistent or worsening pattern, not a single symptom, is what should prompt assessment.

The second mistake runs the other way: a shadow on a scan that is called a tumor but is something else. Arachnoid cysts, fluid-filled pockets in the membranes around the brain, are usually harmless. Cavernous malformations and other vascular lesions can look tumor-like. Areas of inflammation, old injury or infection can enhance with contrast just as tumors do. Even a tiny pituitary finding may be a normal variant rather than an adenoma. This is why the first specialist appointment after an unexpected scan is often more reassuring than people expect: an experienced neuroradiologist re-reads the images and sometimes downgrades the finding entirely.

Where imaging cannot settle the question, a repeat scan after an interval is a legitimate diagnostic tool. Tumors change; scars and cysts generally do not. In that sense, a short period of watching is sometimes the way a diagnosis is made, not just the way it is managed.

What people often get wrong about watching a brain tumor

Misunderstandings cluster around surveillance, and several of them cause real harm, either by driving people toward surgery they do not need or by making the waiting unbearable.

“Benign means harmless.” Not quite. Benign means non-cancerous: the tumor does not invade tissue or spread elsewhere. Inside a closed skull, a benign tumor in the wrong place can still press on vital structures. This is precisely why benign tumors are monitored rather than dismissed.

“They’re only watching because they can’t operate.” Usually the opposite. Surveillance is most often recommended when the tumor could be removed but the risks of surgery outweigh the risks of leaving it. A team that watches is keeping surgery in reserve, not writing it off.

“Every tumor eventually grows.” Many small meningiomas and acoustic neuromas stay the same size across years of scans. Mayo Clinic notes that acoustic neuromas may grow slowly or not at all. Stability is a common outcome, not a lucky exception.

“Repeated MRI scans are dangerous.” MRI uses magnets and radio waves, not ionizing radiation. The main practical concerns are the contrast dye in people with kidney problems and metal implants, both of which are screened for.

“A special diet or supplement can shrink it.” There is no reliable evidence that any diet, herb or supplement shrinks brain tumors. Eating well supports general health, which matters if treatment is ever needed, but it is not tumor therapy, and anyone selling it as such should be treated with caution.

“If I have a headache, the tumor is growing.” Headache is common; tumor growth between scheduled scans that announces itself only as an ordinary headache is not. The specific warning patterns are set out below, and they are different from everyday headache.

Questions to ask your care team about brain tumor active surveillance

A surveillance consultation can feel over before you have gathered your thoughts. Taking a written list, and someone to take notes, is one of the more useful things you can do. These questions tend to draw out the information that matters.

• What do you think this tumor is, and how confident are you from the imaging alone?
• What features of my tumor make watching a reasonable choice, and what features would make you change your mind?
• How large is it now, in millimeters or volume, and can I have copies of each report?
• When is the next scan, and what would you expect to see if the tumor is behaving?
• What symptoms should prompt me to call before the next scheduled scan, and who exactly do I call?
• If it grows, what are the options, and would waiting until then make any of those options harder or riskier?
• Are there other tests I should have alongside the MRI, such as hearing, vision or hormone checks?
• Does this diagnosis affect my driving, my work, travel insurance or any medicines I take?
• Is there a specialist nurse or coordinator I can contact between appointments?
• If I decided I would rather have treatment now, what would you advise, and why?

That last question deserves emphasis. Surveillance is a shared decision, and preference is a legitimate part of it. Some people, having heard everything, choose earlier treatment for peace of mind; others choose to wait for as long as the scans allow. A team that explains its reasoning and then respects your choice is doing its job well. Where you feel unsure, asking for a second opinion, ideally from a center that sees many such tumors, is standard practice and should never need justifying.

When to call your doctor

Surveillance works only if the person being watched knows what should not wait for the next appointment. The red flags below are drawn from the symptom guidance published by the NHS and Mayo Clinic for brain tumors in general, and they apply whether or not you have a known tumor.

Call emergency services immediately for a first-ever seizure; sudden weakness or numbness on one side of the body; sudden difficulty speaking or understanding speech; sudden severe headache unlike any before; or a sudden drop in alertness or new confusion. These can signal bleeding, blocked fluid pathways or a stroke, and they need same-hour assessment regardless of cause.

Contact your care team promptly, the same day or the next working day, for a headache that is new in character, that is worst on waking or wakes you from sleep, or that comes with persistent nausea or vomiting; for progressive changes in vision, including double vision or loss of part of your visual field; for steadily worsening hearing, ringing in one ear or imbalance if your tumor sits on the hearing nerve; for new clumsiness, changes in personality or memory noticed by others, or unusual drowsiness; and, for pituitary tumors, for symptoms such as unexplained tiredness, dizziness on standing or changes in menstrual cycles that might indicate hormone disturbance.

Use the routine contact route for anything that puzzles or worries you between scans, even if it does not fit the list. A specialist nurse would far rather field a call about an ordinary headache than learn afterward that a significant symptom was sat on for weeks.

None of this replaces the judgment of the team that knows your scans. If in doubt, call. The whole point of choosing to watch is that someone is watching.

Frequently asked questions

What does brain tumor active surveillance actually involve?

Active surveillance means the tumor is left in place and tracked with scheduled MRI scans and clinical check-ups rather than treated immediately. A baseline scan records the tumor’s size, and each follow-up is compared against it for growth, changes in appearance or new swelling. Depending on location, hearing tests, vision tests or hormone blood work may be added. The plan is reviewed by the treating team after every scan.

I have an incidental brain tumor found on MRI. Does that mean it is dangerous?

Not necessarily. A tumor found by chance on a scan done for another reason is, by definition, not causing the symptoms that prompted the scan. Many incidental findings are small meningiomas or other slow-growing, non-cancerous tumors. A specialist review of the images will assess type, size and location and decide whether monitoring, further tests or treatment is appropriate. Some findings are reclassified as cysts or normal variants after expert re-reading.

How often is an MRI done for brain tumor monitoring?

Typically more often at first, then less often if the tumor is stable. An early repeat scan within the first several months checks for rapid growth. After that, Mayo Clinic describes monitoring intervals for acoustic neuromas of roughly every 6 to 12 months, a pattern similar for small meningiomas. Intervals may lengthen further after years of stability. Your treating team sets the schedule for your particular tumor.

What are 10 warning signs of a brain tumor?

There is no fixed list of ten. The NHS and Mayo Clinic describe symptoms in categories: headaches that are new, persistent or worst on waking; seizures; persistent nausea or vomiting; progressive weakness or numbness on one side; vision or speech problems; changes in personality, memory or behavior; unsteadiness; and drowsiness. Each is far more often caused by something other than a tumor, so a persistent or worsening pattern is what warrants medical assessment.

What are usually the first signs of a brain tumor?

It depends on where the tumor sits and how fast it grows. Slow-growing tumors often cause no symptoms for years and are found incidentally. When symptoms do appear, common early ones include a change in headache pattern, a first seizure in an adult, gradual one-sided hearing loss for tumors on the hearing nerve, or subtle changes in vision or personality. None of these is specific, and evaluation by a doctor is the only way to know.

How long can a brain tumor go undiagnosed?

Slow-growing benign tumors can be present for many years before diagnosis, because the brain adapts to gradual pressure and symptoms may be subtle or absent. The NHS notes that benign brain tumors often grow slowly over years, which is why so many are discovered incidentally. Fast-growing tumors, by contrast, usually declare themselves within months with more abrupt symptoms and are not candidates for watching.

What is commonly mistaken for a brain tumor?

Migraine is the most frequent mimic, since it can produce visual disturbance, one-sided numbness, word-finding difficulty and severe headache. Tension headache, sinus disease, inner-ear vertigo, anxiety, multiple sclerosis and brief stroke-like episodes can also resemble tumor symptoms. The reverse also happens: arachnoid cysts, vascular malformations or areas of inflammation on a scan can be mistaken for tumors until reviewed by a neuroradiologist or rescanned.

Is meningioma watch and wait safe for younger people?

It can be, but the calculation differs. A younger person has more decades in which a slow-growing tumor could enlarge, so surgeons may lean toward earlier treatment for a tumor that would simply be watched in someone older. Small, calcified, symptom-free meningiomas in quiet locations may still be monitored at any age. The treating team weighs growth potential, location and the person’s own preferences.

Can a monitored brain tumor shrink or disappear on its own?

Rarely. Most benign brain tumors under surveillance either stay the same size or grow slowly; spontaneous shrinkage is uncommon, though some meningiomas appear to stop growing entirely. No diet, supplement or alternative therapy has been shown in reliable evidence to shrink brain tumors. Stability over years of scans is a common and reassuring outcome, and it is the reason surveillance is offered in the first place.

Can I exercise, travel and work normally while my brain tumor is being monitored?

Usually yes. A small, symptom-free tumor under surveillance does not generally restrict exercise, work or travel, though you should tell any doctor treating you about the diagnosis and carry a summary when abroad. Driving may be affected if you have had a seizure, and rules vary by jurisdiction. Ask your care team about any specific limits for your tumor’s location, and check travel insurance disclosure requirements.

References

• NHS: Benign brain tumour (non-cancerous)
• Cleveland Clinic: Meningioma
• NHS: Brain tumours, symptoms

This article is for general information only and is not a substitute for professional medical advice. Please consult a qualified doctor about your individual situation.